SEER-3: A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2023
This article has no abstract
Epistemonikos ID: 4dd196afaefaf8cb89e50e93feaa37355d768658
First added on: Mar 21, 2025